Medidata Medidata

MassMEDIC Patient Data & Analytics Webcast

Watch On Demand

The New World: Connecting the Next Generation of Patient Data and Devices with Deep Analytics for Commercial Success

Every day, hospitals, doctors, and life science companies collect infinite amounts of data on individual patients, diseases, and medical procedures. The rise of a new generation of robotic, precision, and surgical devices has created boundless stores of video, imaging, and other electronic surgical notes, while the proliferation of digital patient technologies—such as electronic medical records, telemetry, wearable sensors and mobile apps—are generating a menu of personalized data for each patient. This leaves us to ask: Beyond acquisition, how do we standardize and harmonize disparate data sources to gain insights and visibility into patient treatments and outcomes? This webinar discusses a use case on the process of building the standardized, multi-faceted dataset to enable deep real-world data analysis for pre-surgical population management, surgical treatment patterns and post-operative outcomes assessment.

Featured Speakers

Troy Schneider
Sr. Director Imaging Strategy
Medidata

Troy Schneider is the Sr. Director of Imaging Strategy responsible for the strategy and business development of growing one of the world’s most sophisticated networks dedicated to providing secure, powerful and intelligent management and workflows of medical images for the life sciences industry.

Aaron Galaznik
Real-World Evidence Head of Research
Acorn AI, a Medidata company

Aaron Galaznik, MD, is the Head of Real World Evidence Solutions at Acorn AI, a Medidata Company.  He has over 10 years of experience in the life sciences industry, with previous roles in Real World Data, Health Economics and Outcomes Research, Market Access and Commercial Analytics at Takeda Oncology and Pfizer.  His therapeutic expertise includes oncology, pain, inflammation, respiratory, and cardiovascular disease, and he has multiple publications and presentations on disease burden, clinical outcomes assessment, real-world comparative effectiveness, treatment persistence, and impact of utilization management.  He received his AB in Biology from Harvard University, his MD from Weill Medical College of Cornell University, and his MBA in Healthcare Management from the Wharton School.